Darolutamide is a novel oral non-steroidal AR inhibitor with a unique chemical structure that binds to AR with high affinity and exhibits strong antagonistic activity, thereby inhibiting receptor function and the growth of prostate cancer cells [106,107,108]. Here, AR is linked to prostate carcinoma.